{"157921":{"#nid":"157921","#data":{"type":"event","title":"Qingfen Pan - Ph.D. Proposal","body":[{"value":"\u003Cp\u003E\u003Cstrong\u003ECommittee\u003C\/strong\u003E:\u003C\/p\u003E\u003Cp\u003EBarbara Boyan, Ph.D., \u003Cstrong\u003EAdvisor\u003C\/strong\u003E\u003Cbr \/\u003EZvi\u0026nbsp;Schwartz, DMD, Ph.D.\u003Cbr \/\u003EJulia Babensee, Ph.D.\u003Cbr \/\u003EManu Platt, Ph.D.\u003Cbr \/\u003EDavid Hart, PH.D.\u003Cbr \/\u003E\u003Cbr \/\u003EOsteoarthritis (OA) is a degenerative disease characterized by joint inflammation, which leads to cartilage matrix degradation, chondrocyte apoptosis, and progressive cartilage degeneration. Current drug therapies aim to ease pain and reduce local inflammation; however, no drug exists that effectively alleviates the disease condition without significant side effects that are typical to anti-inflammatory drugs. 24R,25-dihydroxyvitamin D3\u0026nbsp;[24R,25(OH)2D3] is an attractive option for articular cartilage repair because of its anti-apoptotic properties in cartilage cells. The\u0026nbsp;\u003Cem\u003Elong-term goal\u003C\/em\u003E\u0026nbsp;of this work is to develop a 24R,25(OH)2D3-based drug therapy for osteoarthritis prevention and articular cartilage repair. The aim of present thesis is to\u0026nbsp;evaluate the use of 24R,25(OH)2D3 as a therapy to prevent the progression of osteoarthritis in\u0026nbsp;\u003Cem\u003Ein vitro\u003C\/em\u003E\u0026nbsp;and\u0026nbsp;\u003Cem\u003Ein vivo\u003C\/em\u003E\u0026nbsp;OA models, and to examine the association of vitamin D3 metabolite levels and severity of osteoarthritis in humans.\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp align=\u0022center\u0022\u003E\u002224R,25-dihydroxyvitamin D3 based Drug Therapy for the Treatment of Osteoarthritis\u0022\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"24R,25-dihydroxyvitamin D3 based Drug Therapy for the Treatment of Osteoarthritis"}],"uid":"27547","created_gmt":"2012-10-01 07:14:06","changed_gmt":"2016-10-08 02:00:10","author":"Chris Ruffin","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2012-10-02T16:00:00-04:00","event_time_end":"2012-10-02T18:00:00-04:00","event_time_end_last":"2012-10-02T18:00:00-04:00","gmt_time_start":"2012-10-02 20:00:00","gmt_time_end":"2012-10-02 22:00:00","gmt_time_end_last":"2012-10-02 22:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"groups":[{"id":"65448","name":"Bioengineering Graduate Program"}],"categories":[],"keywords":[{"id":"569","name":"bioengineering"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1788","name":"Other\/Miscellaneous"}],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:chris.ruffin@ibb.gatech.edu\u0022\u003EMr. Chris Ruffin\u003C\/a\u003E\u003C\/p\u003E","format":"limited_html"}],"email":[],"slides":[],"orientation":[],"userdata":""}}}